The agreement was signed in September 2011, and a meeting between the CEO and CFO of Ergomed and Hikma’s CEO and management team was held on Wednesday January 18. Ergomed will be conducting the first clinical trials for one of Hikma’s key oncology (anti-cancer) products in Jordanian hospitals with plans of potential expansion in the MENA region. In turn, Hikma will provide Ergomed with an expanded insight into the regional pharmaceutical sector.

Mr Said Darwazah, CEO of Hikma Pharmaceuticals, stated, “We are very pleased to announce the commencement of our partnership with Ergomed. They have a well-deserved reputation for excellence in the pharmaceutical sector and they will enhance Hikma’s ability to provide the best treatments for patients in Jordan and across the MENA region. As organisations, Hikma and Ergomed complement each other well, with great potential for operational synergies.”

“Our decision to work with Ergomed comes from a strong commitment to continuous medical advancement through the use of clinical trials, especially in the field of oncology. We are the leading company in our sector, and we want to continue providing the optimum treatments to our patients. Collaborating with Ergomed will ensure that we do so.”

Dr Miroslav Reljanovic, CEO of Ergomed, stated, “We are very pleased to be working with Hikma on these initiatives. Ergomed has over thirteen years experience of international drug development and is currently developing a full service MENA business managed from its Dubai head office.

We share Hikma’s proven commitment to quality and to meeting the needs of doctors and patients and we look forward to working on this and future projects”